Zosano Pharma, Inc. Completes Positive End-of-Phase 2 Meeting With FDA Regarding ZP-PTH Patch for Osteoporosis
FREMONT, Calif.--(BUSINESS WIRE)--Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, today announced that it has completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its ZP-PTH rapid delivery patch for the treatment of osteoporosis in women at high risk of fracture.